Denali Therapeutics uses its proprietary TransportVehicle™ platform to deliver enzyme‑based biologics across physiological barriers, enabling treatment of neurodegenerative diseases and lysosomal storage disorders throughout the body, including the brain. The company’s pipeline includes multiple investigational candidates and the FDA‑approved therapy AVLAYAH™ for Hunter syndrome, demonstrating its ability to create disease‑modifying treatments for serious unmet medical needs.
Funding
$500M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many serious diseases, such as neurodegenerative disorders and lysosomal storage diseases, lack effective treatments because therapeutic proteins and enzymes cannot efficiently cross biological barriers like the blood‑brain barrier or reach target tissues in sufficient quantities.
Solution
Denali Therapeutics addresses this gap with its proprietary TransportVehicle™ platform, a technology that enables the delivery of biologic therapeutics across physiological barriers to the whole body, including the central nervous system. The platform is used to engineer enzyme‑based biotherapeutics that can restore deficient enzymatic activity in lysosomal storage disorders and modulate disease pathways in neurodegenerative conditions. Denali’s pipeline includes multiple investigational candidates and an FDA‑approved therapy (AVLAYAH™) for Hunter syndrome, demonstrating the platform’s clinical viability. By integrating advanced protein engineering, targeted delivery mechanisms, and scalable manufacturing, the company aims to bring disease‑modifying treatments to patients with unmet medical needs.
Target Audience
Primary customers are pharmaceutical partners, biotech companies, and clinical researchers developing enzyme‑based or protein therapeutics for neurodegenerative and lysosomal storage diseases, as well as patients and caregivers seeking access to advanced treatments.
Features
- TransportVehicle™ platform that couples therapeutic enzymes to carrier molecules for efficient trans‑barrier transport
- Engineered enzyme biologics designed to restore deficient activity in lysosomal storage disorders such as Hunter, Sanfilippo, and Pompe diseases
- Clinical programs targeting neurodegenerative diseases, leveraging the platform’s ability to deliver proteins to the brain
- FDA‑approved AVLAYAH™ (tividenofusp alfa‑eknm) as a commercial proof point of the technology
- Early access program (EAP) to provide investigational therapies to patients with serious or life‑threatening conditions before regulatory approval
- Collaborative approach with patient communities to inform trial design and therapeutic priorities